ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Voyager Therapeutics Inc

Voyager Therapeutics Inc (VYGR)

8.51
-0.29
(-3.30%)
Closed June 15 4:00PM
8.51
-0.005
(-0.06%)
After Hours: 7:08PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
8.51
Bid
8.45
Ask
8.60
Volume
378,146
8.45 Day's Range 8.77
6.06 52 Week Range 14.07
Market Cap
Previous Close
8.80
Open
8.65
Last Trade
3
@
8.6
Last Trade Time
Financial Volume
$ 3,229,304
VWAP
8.5398
Average Volume (3m)
495,532
Shares Outstanding
54,300,627
Dividend Yield
-
PE Ratio
3.49
Earnings Per Share (EPS)
2.44
Revenue
250.01M
Net Profit
132.33M

About Voyager Therapeutics Inc

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the produc... Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
1970
Voyager Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker VYGR. The last closing price for Voyager Therapeutics was $8.80. Over the last year, Voyager Therapeutics shares have traded in a share price range of $ 6.06 to $ 14.07.

Voyager Therapeutics currently has 54,300,627 shares outstanding. The market capitalization of Voyager Therapeutics is $462.10 million. Voyager Therapeutics has a price to earnings ratio (PE ratio) of 3.49.

VYGR Latest News

Voyager Therapeutics to Present at Multiple Virtual Investor Conferences

LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the...

Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.121.430274135888.399.068.23121008.67787722CS
4-0.16-1.845444059988.679.067.683750828.40589559CS
12-0.95-10.04228329819.4610.667.264955328.6511317CS
260.556.909547738697.9611.727.017082018.8027557CS
52-4.79-36.01503759413.314.076.065187139.04952693CS
1563.7879.91543340384.7314.33982.468793345.84078313CS
260-16.11-65.434606011424.6228.792.466834977.12247004CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
KAVLKaival Brands Innovations Group Inc
$ 5.96
(338.24%)
70.99M
LRHCLa Rosa Holdings Corporation
$ 1.165
(90.61%)
40.6M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
BRFHBarfresh Food Group Inc
$ 3.03
(38.36%)
247.31k
NNENano Nuclear Energy Inc
$ 9.37
(32.53%)
1.77M
NXLNexalin Technologies Inc
$ 0.89
(-35.52%)
3.93M
INABIN8bio Inc
$ 1.095
(-34.82%)
4.92M
QXOQXO Inc
$ 134.10
(-34.71%)
142.29k
GANXGain Therapeutics Inc
$ 1.24
(-34.39%)
3.09M
KYTXKyverna Therapeutics Inc
$ 9.52
(-34.07%)
4.31M
NVDANVIDIA Corporation
$ 131.88
(1.75%)
309.34M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
KITTNauticus Robotics Inc
$ 0.1921
(19.69%)
165.83M
CRKNCrown Electrokinetics Corporation
$ 0.0582
(-21.35%)
136.77M
SQQQProShares UltraPro Short QQQ
$ 8.43
(-1.29%)
112.46M

VYGR Discussion

View Posts
PonkenPlonken PonkenPlonken 1 month ago
will be bought out. So many milestones to be paid.
👍️0
Monksdream Monksdream 1 month ago
VYGR under $10

👍️0
tedpeele tedpeele 3 months ago
Target price $30 by Wainwright - was only a matter of time - the analysts were completely wrong and blown away by both the revenues and eps last quarter.
👍️0
tedpeele tedpeele 3 months ago
Holy smokes - $3 EPS on HUGE revenue increase: https://www.otcmarkets.com/stock/VYGR/financials
👍️0
Jess070283 Jess070283 4 months ago
Insider dumping=easy short.
👍️0
Invest-in-America Invest-in-America 4 months ago
VYGR: Insider dumping --- at the Firm, & their Homeboys & Homegirls. SAD!!! (TRUTH be told.)
👍️0
Jess070283 Jess070283 4 months ago
Is the next pump and dump? Asking for a friend…
👍️0
tedpeele tedpeele 4 months ago
As of December 31, 2023, our cash, cash equivalents, and marketable securities were $230.9 million. Based upon our current operating plan, we expect that our existing cash, cash equivalents, and marketable securities at December 31, 2023, together with the $80.0 million upfront payment received in January 2024 in connection with the 2023 Novartis Collaboration Agreement, the $20.0 million in proceeds from Novartis’ stock purchase, and the $93.5 million in net proceeds received from our public offering in January 2024, along with amounts expected to be received as reimbursement for development costs under our collaboration and license agreements with Neurocrine and Novartis, certain near term milestones, and interest income, to be sufficient to meet our planned operating expenses and capital expenditure requirements into 2027.
👍️0
tedpeele tedpeele 4 months ago
incredible - blows away the analysts
👍️0
Invest-in-America Invest-in-America 4 months ago
VYGR: Big news!! HUGE NET INCOME, vs. net LOSS of last report.
https://finance.yahoo.com/news/voyager-therapeutics-inc-vygr-announces-214155031.html
👍️0
north40000 north40000 5 months ago
We have 500 shares in each of 2 accounts. Both are profitable, entry ~ $4 in the IRA, LTCG. XBI, IBB negative today. No worries, but Fed bears watching, eh?
👍️0
Gary Ray Gary Ray 5 months ago
News? Bankruptcy imminent. Sheeple woke up from COVID scare and know this and med companies are a sham
👍️0
north40000 north40000 5 months ago
Off > $3 from your post 2 weeks later. Trading at $7.12 at 1:50 pm today. News? None that I see.
👍️0
TheFinalCD TheFinalCD 5 months ago
VYGR 10.93 NHOD
👍️0
subslover subslover 5 months ago
Yeah! Nice! :)
👍️0
TheFinalCD TheFinalCD 5 months ago
VYGR avg 9.51 just sold 10.51 (+$1/share) and its still going
👍️0
TheFinalCD TheFinalCD 5 months ago
i am in avg 9.54 and its 8.95

SMH

that news is yuge

but they sold it off

SMH
👍️0
TheFinalCD TheFinalCD 5 months ago
correction HNY

not HPN

lol
👍️0
TheFinalCD TheFinalCD 5 months ago
HPN $VYGR LOOKIN GOOD ON NEWS https://dilutiontracker.com/app/search/VYGR?a=dbb88c

oday 10:46AM
VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today
(InvestorPlace) +24.32%
10:36AM
Novartis Sweetens Its Deal With Voyager, And VYGR Stock Up 29% Flashes A Bullish Sign
(Investor's Business Daily)
07:36AM
UPDATE 2-Novartis signs gene therapy deal with Voyager for $100 mln upfront
(Reuters)
07:14AM
Voyager Therapeutics shares jump after $1.2 billion deal with Novartis
(Reuters)
07:14AM
Novartis signs gene therapy deal with Voyager for $100 mln upfront
(Reuters)
👍️0
subslover subslover 5 months ago
NEWS
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies
- Collaboration with gene therapy leader Novartis aims to discover and develop new approaches for Huntington’s disease and spinal muscular atrophy -

- Voyager to receive up-front consideration of $100 million and is eligible to receive milestone payments and tiered royalties -

LEXINGTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS) to advance potential gene therapies for Huntington’s disease (HD) and spinal muscular atrophy (SMA). Voyager will provide Novartis a target-exclusive license to access Voyager’s TRACER™ capsids and other intellectual property for the respective diseases, and Voyager and Novartis will collaborate to advance a preclinical gene therapy candidate for HD.

“We are thrilled to expand our existing relationship with Novartis, a global leader in the gene therapy field,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “Combining the proven capabilities of Novartis in gene therapy development and commercialization with Voyager’s next-generation TRACER capsids and payloads could enable the advancement of important new therapies for patients. In addition, the consideration Voyager will receive from this collaboration will strengthen our balance sheet and extend our runway into mid-2026.”

“We look forward to broadening our work with Voyager to help bring forward novel, high-impact gene therapies with the potential to improve the lives of patients affected by severe neurologic conditions,” said Fiona Marshall, President of Biomedical Research at Novartis. “We believe Voyager’s TRACER capsids hold promise for enabling next-generation gene therapies for diseases of the central nervous system, aligning well with our deep neuroscience expertise and gene therapy leadership at Novartis.”

Novartis previously exercised options to license novel capsids generated from Voyager’s TRACER capsid discovery platform for use in gene therapy programs against two undisclosed neurological disease targets.

Collaboration Details and Financial Terms
Under the terms of the agreement, Novartis has agreed to pay Voyager $100 million of consideration up front, including a $20 million purchase of newly issued equity in Voyager. Voyager is eligible to receive up to $1.2 billion in preclinical, development, regulatory and sales milestones, as well as tiered royalties on global net sales of products incorporating Voyager’s TRACER capsids. Novartis will obtain target-exclusive access to Voyager’s TRACER capsids related to SMA for the duration of the agreement and will be responsible for all development and commercialization. Novartis will also receive worldwide rights to Voyager’s AAV gene therapy for HD, leveraging Voyager’s TRACER capsids and proprietary payloads. Voyager will be responsible for preclinical advancement and Novartis will be responsible for all clinical development and commercialization for the HD program.

Chestnut Partners served as exclusive financial advisor to Voyager on this transaction.

About the TRACER™ Capsid Discovery Platform
Voyager’s TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) capsid discovery platform is a broadly applicable, RNA-based screening platform that enables rapid discovery of AAV capsids with robust penetration of the blood-brain barrier and enhanced central nervous system (CNS) tropism in multiple species, including non-human primates (NHPs). In preclinical studies, TRACER generated capsids have demonstrated widespread gene expression in the CNS compared to conventional AAV capsids as well as cell- and tissue-specific transduction, including to areas of the brain that have been traditionally difficult to reach, while de-targeting the liver and dorsal root ganglia. As part of its external partnership strategy, Voyager has established multiple collaboration agreements providing access to its next-generation TRACER capsids to potentially enable its partners’ gene therapy programs to treat a variety of diseases.

About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit www.voyagertherapeutics.com.

Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.

Forward-Looking Statements
👍️0
Gary Ray Gary Ray 11 months ago
Too bad they killed this one. Should have gone to $25-40 easily
👍️0
Elgordo84 Elgordo84 11 months ago
I’ll be watching $9.05 to $7.85 very closely
#GLTA
#ELGORDODAMUS
$VYGR
👍️0
Gary Ray Gary Ray 11 months ago
Eat a Dk vygr. Can’t stay hard huh?
👍️0
Elgordo84 Elgordo84 1 year ago
Nice run on $VYGR
$5.68 to $10.77
In 4 month not a bad trade..
#ELGORDODAMUS
👍️0
Gary Ray Gary Ray 1 year ago
Entice new guppies. You know how we do :)
👍️0
TheFinalCD TheFinalCD 1 year ago
8.25 hmmmm
👍️0
TheFinalCD TheFinalCD 1 year ago
indeed .....aGREED
👍️0
Gary Ray Gary Ray 1 year ago
Gap up! Trap that new young blood LOL
👍️0
TheFinalCD TheFinalCD 1 year ago
$VYGR NEWS https://finance.yahoo.com/news/neurocrine-biosciences-voyager-therapeutics-enter-120000143.html
👍️0
Elgordo84 Elgordo84 2 years ago
It’s about to get really interesting on this Board
Let’s go $VYGR
#ELGORDODAMUS
👍️0
Gary Ray Gary Ray 2 years ago
Up like an escalator down like an elevator.
Good stuff
👍️0
Gator44 Gator44 2 years ago
$9.74
new 52wh
👍️0
Gator44 Gator44 2 years ago
OK in for $2.86
👍️0
Gator44 Gator44 3 years ago
VYGR. filled the gap at $3.60
👍️0
BPETER BPETER 3 years ago
Soon that will be 1 or more years ???
👍️0
Roadtojourney Roadtojourney 3 years ago
1 day up another 4 days down, pump and dump pos imo, hope it starts going up man.
👍️0
ttottip ttottip 3 years ago
Come on! Enough with the red days!
👍️0
Gary Ray Gary Ray 3 years ago
Cause fluff yo. News out, time to exit.
Was a good run prior to news
And then they killed the run
Just click the short button
👍️0
ttottip ttottip 3 years ago
Why this is dropping every day??? When we'll start moving up? I'm too much down, but hope this will recover soon. Red days can't last forever.
👍️0
Gary Ray Gary Ray 3 years ago
Told you it’s garbage LOLOLOL
Not even a consolidation.
Easiest short plain and simple
👍️0
ttottip ttottip 3 years ago
https://www.tradingview.com/symbols/NASDAQ-VYGR/technicals/ BUY ,BUY, BUY!
👍️0
ttottip ttottip 3 years ago
I think this will be green by then.
👍️0
BPETER BPETER 3 years ago
👍️0
Gary Ray Gary Ray 3 years ago
LOL. I’m seeing low 4s by lunch
👍️0
ttottip ttottip 3 years ago
This looks great today. Soon we'll break the HOD.
👍️0
ttottip ttottip 3 years ago
Why? Red again today? I'm down. I bought yesterday at 4.65.
👍️0
Gary Ray Gary Ray 3 years ago
Not a chance :)
👍️0
ttottip ttottip 3 years ago
If we reach the 5's, we'll remain there this time.
👍️0
Gary Ray Gary Ray 3 years ago
Good morning!!! Doubtful
👍️0
ttottip ttottip 3 years ago
Good morning all! Let's hope this time we'll hold the gains!
👍️0

Your Recent History

Delayed Upgrade Clock